Emmace Consulting will participate in yet another project (Grant #75F40119C10154) sponsored by US Food and Drug Administration (FDA). The company will use its methods and models to conduct studies that may challenge current pharmacopeia methods. The project spans two years and will be carried out in collaboration with the University of Florida. Emmace Consulting has internationally recognized expertise in inhalation studies. The company will carry out studies to simulate how the dose of medicine from a range of commercial inhalers reaches the lungs under various conditions and in different patients. One aim is to explore whether a new method of analysis, which is more clinically relevant and potentially more robust than the method described in current pharmacopeia, should replace it. The company will apply its unique methods and models in the studies, including various oral cavity castings and a "mechanical hand" that applies standardized hand pressure when dosing and can be actuated at any point in the inhalation maneuver. Emmace Consulting has recently participated in FDA-funded research projects since 2015, such as grant #U01FD004943, in which the University of Florida is the Principal Investigator (PI). “We are immensely pleased to take part in a second research project. It shows that our expertise is of the highest quality and meets the requirements that the FDA expects. The comprehensive project will account for a substantial portion of our revenue over a two-year period,” says Mårten Svensson, CEO and founder of Emmace Consulting. For more information, please contact: Mårten Svensson, CEO and founder of Emmace Consulting, firstname.lastname@example.org, telephone: +46 (0)709-59 45 53 Emmace Consulting: Emmace Consulting offers excellence in advising and performance testing of pharmaceutical products on a CRO-basis. Our strengths are in the following areas: Traditional testing [...]
Emmace Consulting, a Swedish Company, was awarded a sub-contract by the University of Florida after they were awarded the U01FD004943 Grant by the FDA. Emmace Consulting, internationally recognized for its expertise in inhalation studies, will conduct a comprehensive series of laboratory studies as part of a larger project during the second quarter of 2019. Since 2015, Emmace Consulting has participated on a small scale in an FDA-funded research project (grant # U01FD004943, which has University of Florida, US, as current grantee). One of the aims of the project is to explore what impact changes in formulation characteristics of metered dose inhalers (MDIs) have on product performance and predicted lung dose in humans. Recently they have been given a significantly larger task within the same project. Emmace Consulting will be carrying out a large series of laboratory studies on metered dose inhalers (sprays) that have been specially produced for the project. The company will analyze the spray pattern and plume geometry of the aerosols. Emmace Consulting will also carry out laboratory analyses using methods that model actual human-like conditions (“in vivo realistic analyses”) in order to estimate the lung dose that is delivered to the patient. The sub-contract also includes investigation of commercial metered-dose inhalers available on the US market using a newly proposed methodology. Results of Emmace Consulting’s work will be published in scientifically peer-reviewed journals. “We are extremely pleased that our expertise is appreciated and hope to have the opportunity to work with them on other projects. The assignment gives us broader recognition as a provider of attractive services for projects by organizations and companies in the field of inhalation drug therapy,” says Mårten Svensson, CEO and founder of Emmace Consulting. For more [...]
Mårten Svensson, CEO of Emmace Consulting is attending RDD 2019 in Portugal and will be happy to discuss how Emmace Consulting can help you develop inhaled products.
Now a proud SmiLe Alumni member! https://www.linkedin.com/feed/update/urn:li:activity:6495303115359817728
Emmace will have a strong presence during the upcoming DDL2018 conference. Please drop by and have a chat with our advisors and specialists. Emmace Consulting is a Bronze Sponsor (booth 314) at Drug Delivery to the Lungs 2018 in Edinburgh 12th-14th December.
Per Bäckman, Senior Inhalation Consultant, now in our team. #amazingstaff ;-) Read more about Emmace Team
Emmace Consulting is attending RDD 2018 in Arizona as a technology exhibitor. Both Bo Olsson and Mårten Svensson will be happy to discuss how Emmace Consulting can help you develop inhaled products. Two posters are also presented. Please drop by and have a chat with us. Bo Olsson is also presenting the Mimetikos Preludium on the podium (Session 6). Don't miss the opportunity to book a personal F2F demonstration of the unique software. Read more about the capabilities of Emmace Consulting and Mimetikos Preludium™ Software.
During the upcoming DDL2017 conference, Dr. Bo Olsson, Senior Advisor at Emmace Consulting, will be happy to demonstrate the Mimetikos Preludium application for anyone interested. Book a F2F meeting with Bo by contacting him at email@example.com. Emmace Consulting is a Bronze Sponsor at Drug Delivery to the Lungs 2017 in Edinburgh 6th-8th December. Come and visit us at booth 314 in The Lennox Suite. Mimetikos Preludium™ software is a modeling package for estimating regional deposition of inhaled aerosols in man. The package is particularly focused on pharmaceutical aerosols but is equally applicable to environmental aerosols. Read more about Mimetikos Preludium™ Software
Emmace Consulting has, in collaboration with S5 Consulting and Jolyon Mitchell Inhaler Consulting Services Inc, jointly published an analytical test approach that is more in-vivo like than the existing pharmacopeia methods. Don’t hesitate to contact the authors for more information.
Joint Research Agreement between Emmace Consulting AB, Mylan Pharma UK LtD and the University of Cyprus
In May 2017, the University of Cyprus (Cyprus), Mylan Pharma UK Ltd (UK), and Emmace Consulting AB entered into a joint research agreement with the aim of developing a state-of-the-art scientific methodology to study upper airway deposition of inhaled medicines. The collaboration will effectively combine the key competencies of the computational Sciences Laboratory at UCY (UCy-CompSci) and their High Performance Computing (HPC) system, the skilled aerosol characterization laboratories at Emmace Consulting AB and the respiratory product development expertise of Mylan Pharma UK Ltd. This collaboration also marks an important milestone for the European Union COST Action MP1404 - “SimInhale” which is coordinated by UCY-CompSci. First results are planned to be reported in the scientific literature in early 2018.